Inactive Instrument
IRLAB Therapeutics AB Share Price Nasdaq Stockholm
Stocks
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Nasdaq Stockholm
|
||
| - SEK | - |
|
| 08-19 | Irlab's IRL757 is assigned the name linepemat by WHO | FW |
| 07-08 | Irlab board member James Gamgort buys shares for just under SEK 0.3m | FW |
| Market Cap | 258M 27.18M 23.29M 21.79M 19.92M 37.6M 2.6B 38M 100M 1.31B 102M 99.85M 4.32B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 258M 27.18M 23.29M 21.79M 19.92M 37.6M 2.6B 38M 100M 1.31B 102M 99.85M 4.32B | EV / Sales 2026 * |
2.53x | EV / Sales 2027 * | 1.82x |
| Free-Float |
86.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: IRLAB Therapeutics AB
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/07/2024 | |
Susanna Waters
PRN | Corporate Officer/Principal | 60 | 31/12/2012 |
Clas Sonesson
CTO | Chief Tech/Sci/R&D Officer | 65 | 31/12/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Rein Piir
BRD | Director/Board Member | 68 | 31/12/2015 |
| Chairman | 73 | 06/05/2020 | |
| Chairman | 68 | 19/02/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | +5.39% | +75.21% | +127.54% | 1,119B | |
| +1.04% | +4.07% | +52.29% | +65.39% | 651B | |
| -0.17% | +5.67% | +25.60% | +80.40% | 468B | |
| -1.38% | +4.02% | +41.64% | +42.38% | 374B | |
| -0.52% | +2.72% | +24.32% | +41.06% | 302B | |
| -1.06% | +4.76% | +1.19% | +12.65% | 259B | |
| +1.03% | +5.83% | +51.11% | +72.96% | 238B | |
| -0.53% | +2.34% | -17.77% | -53.66% | 208B | |
| +0.42% | +5.63% | +27.86% | +92.24% | 181B | |
| Average | -0.20% | +4.81% | +31.27% | +53.44% | 422.21B | |
| Weighted average by Cap. | -0.23% | +4.95% | +43.93% | +72.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 102M 10.75M 9.21M 8.62M 7.88M 14.87M 1.03B 15.03M 39.66M 517M 40.37M 39.5M 1.71B | 142M 14.95M 12.81M 11.98M 10.96M 20.67M 1.43B 20.89M 55.14M 719M 56.12M 54.91M 2.38B |
| Net income | -32.6M -3.44M -2.94M -2.75M -2.52M -4.75M -329M -4.8M -12.68M -165M -12.9M -12.62M -547M | 33.3M 3.51M 3.01M 2.81M 2.57M 4.86M 336M 4.91M 12.95M 169M 13.18M 12.89M 558M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Calendar
Select your edition
All financial news and data tailored to specific country editions
